Download PDF
Open Access
CC BY-NC-ND 4.0 · World J Nucl Med 2021; 20(01): 32-37
DOI: 10.4103/wjnm.WJNM_33_20
Original Article

The findings of 18F-fluorodeoxyglucose positron emission tomography–computed tomography scan in patients with hidradenitis suppurativa in Malaysia: A multicenter study

Authors

  • Chai Loo

    1   Department of Dermatology, Hospital Kuala Lumpur, Kuala Lumpur
    2   Department of Dermatology, Hospital Pulau Pinang, Penang

  • Alex Khoo

    3   Department of Nuclear Medicine, Hospital Adventist, Penang

  • Wooi Tan

    2   Department of Dermatology, Hospital Pulau Pinang, Penang

  • Yek Khor

    2   Department of Dermatology, Hospital Pulau Pinang, Penang

  • Jyh Tang

    4   Department of Dermatology, Hospital Raja Permaisuri Bainun, Ipoh, Malaysia

  • Min Tang

    1   Department of Dermatology, Hospital Kuala Lumpur, Kuala Lumpur

  • Lee Chan

    2   Department of Dermatology, Hospital Pulau Pinang, Penang
Further Information
Also available at
  Permissions and Reprints

Abstract

Hidradenitis suppurativa (HS) is known to have association with systemic diseases with chronic inflammation such as psoriasis. We aim to describe the concomitant systemic inflammation in patients with HS using 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET/CT) scan. This was a case–control study conducted in three tertiary hospitals in Northern Malaysia from January to December 2017, involving HS patients aged 18 years and above. Thirty-two HS patients with age- and sex-matched controls were recruited with a mean age of 31.4 years (range: 18–56). Numerous cutaneous inflammatory foci were detected on FDG-PET/CT scan in clinically unapparent sites (27/32, 84.4%). Approximately 90.6%, 93.8%, and 50.0% of the patients had significantly higher cutaneous uptake over nasal, mandibular, and scalp regions, respectively (P < 0.0001). PET/CT scan did not detect any systemic inflammation unlike those found in psoriasis. Three (9.4%) patients had thyroid nodules with high uptake (maximum standard uptake values ranging from 2.9 to 11.3). Two of them were confirmed to have papillary thyroid carcinoma, while the third patient has inconclusive finding. 18F-FDG PET/CT scan may be useful to map disease burden of HS. Nonlesional inflammatory foci on the skin of the nose, mandibular, and scalp are probably significant. The association of thyroid carcinoma in HS warrants further evaluation.

Keywords

Hidradenitis suppurativa - imaging - Malaysia - positron emission tomography–computed tomography scan - thyroid carcinoma

Financial support and sponsorship

Nil.




Publication History

Received: 27 May 2020

Accepted: 26 June 2020

Article published online:
30 March 2022

© 2021. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Miller IM, Ellervik C, Vinding GR, Zarchi K, Ibler KS, Knudsen KM, et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014;150:1273-80.
  • 2 Shalom G, Freud T, Harman-Boehm I, Polishchuk I, Cohen AD. Hidradenitis suppurativa and metabolic syndrome: A comparative cross-sectional study of 3207 patients. Br J Dermatol 2015;173:464-70.
  • 3 Crowley JJ, Mekkes JR, Zouboulis CC, Scheinfeld N, Kimball A, Sundaram M, et al. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol 2014;171:1561-5.
  • 4 Gold DA, Reeder VJ, Mahan MG, Hamzavi IH. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 2014;70:699-703.
  • 5 Hess S, Hansson SH, Pedersen KT, Basu S, Høilund-Carlsen PF. FDG-PET/CT in infectious and inflammatory diseases. PET Clin 2014;9:497-519, vi-vii.
  • 6 Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): A pilot study. Arch Dermatol 2011;147:1031-9.
  • 7 Wortsman X, Moreno C, Soto R, Arellano J, Pezo C, Wortsman J. Ultrasound in-depth characterization and staging of hidradenitis suppurativa. Dermatol Surg 2013;39:1835-42.
  • 8 Wortsman X. Imaging of hidradenitis suppurativa. Dermatol Clin 2016;34:59-68.
  • 9 Wortsman X, Wortsman J. Clinical usefulness of variable-frequency ultrasound in localized lesions of the skin. J Am Acad Dermatol 2010;62:247-56.
  • 10 Griffin N, Williams AB, Anderson S, Irving PM, Sanderson J, Desai N, et al. Hidradenitis suppurativa: MRI features in anogenital disease. Dis Colon Rectum 2014;57:762-71.
  • 11 Kelly AM, Cronin P. MRI features of hidradenitis suppurativa and review of the literature. AJR Am J Roentgenol 2005;185:1201-4.
  • 12 Salomon T, Nganoa C, Gac AC, Fruchart C, Damaj G, Aide N, et al. Assessment of alteration in liver 18F-FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score. Eur J Nucl Med Mol Imaging 2018;45:941-50.
  • 13 Simpson RC, Dyer MJ, Entwisle J, Harman KE. Positron emission tomography features of hidradenitis suppurativa. Br J Radiol 2011;84:e164-5.
  • 14 Asamoah P, Wale DJ, Viglianti BL, Wong KK, Gross M. Multiple hypermetabolic subcutaneous lesions from hidradenitis suppurativa mimicking metastases on 18F-FDG PET/CT. Clin Nucl Med 2018;43:73-4.
  • 15 Poh F, Wong SK. Imaging of hidradenitis suppurativa and its complications. Case Rep Radiol 2014;2014:294753.
  • 16 Vinkel C, Thomsen SF. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne. Int J Dermatol 2017;56:811-8.
  • 17 De Vita V, McGonagle D. Hidradenitis suppurativa as an autoinflammatory keratinization disease. J Allergy Clin Immunol 2018;141:1953.
  • 18 Akiyama M, Takeichi T, McGrath JA, Sugiura K. Autoinflammatory keratinization disease. J Allergy Clin Immunol 2017;140:1545-7.
  • 19 Kelly G, Hughes R, McGarry T, van den Born M, Adamzik K, Fitzgerald R, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol 2015;173:1431-9.
  • 20 Loo CH, Tan WC, Tang JJ, Khor YH, Manikam MT, Low DE, et al. The clinical, biochemical, and ultrasonographic characteristics of patients with hidradenitis suppurativa in Northern Peninsular Malaysia: A multicenter study. Int J Dermatol 2018;57:1454-63.
  • 21 Liu M, Davis JW, Idler KB, Mostafa NM, Okun MM, Waring JF. Genetic analysis of NCSTN for potential association with hidradenitis suppurativa in familial and nonfamilial patients. Br J Dermatol 2016;175:414-6.
  • 22 Canoui-Poitrine F, Le Thuaut A, Revuz JE, Viallette C, Gabison G, Poli F, et al. Identification of three hidradenitis suppurativa phenotypes: Latent class analysis of a cross-sectional study. J Invest Dermatol 2013;133:1506-11.
  • 23 Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis. J Am Acad Dermatol 2014;71:1144-50.
  • 24 Makris GM, Poulakaki N, Papanota AM, Kotsifa E, Sergentanis TN, Psaltopoulou T. Vulvar, perianal and perineal cancer after hidradenitis suppurativa: A systematic review and pooled analysis. Dermatol Surg 2017;43:107-15.
  • 25 Sotoodian B, Abbas M, Brassard A. Hidradenitis suppurativa and the association with hematological malignancies. J Cutan Med Surg 2017;21:158-61.
  • 26 Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003;88:4100-4.
  • 27 Choi JY, Lee KS, Kim HJ, Shim YM, Kwon OJ, Park K, et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: Clinical significance and improved characterization. J Nucl Med 2006;47:609-15.
  • 28 Flukes S, Lenzo N, Moschilla G, Sader C. Positron emission tomography-positive thyroid nodules: Rate of malignancy and histological features. ANZ J Surg 2016;86:487-91.
  • 29 Bertagna F, Treglia G, Piccardo A, Giubbini R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab 2012;97:3866-75.
  • 30 Katz SC, Shaha A. PET-associated incidental neoplasms of the thyroid. J Am Coll Surg 2008;207:259-64.
  • 31 Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001;130:941-6.
  • 32 Sheikhbahaei S, Marcus C, Subramaniam RM. 18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes. PET Clin 2015;10:125-45.
  • 33 Kaliszewski K, Strutyńska-Karpińska M, Zubkiewicz-Kucharska A, Wojtczak B, Domosławski P, Balcerzak W, et al. Should the prevalence of incidental thyroid cancer determine the extent of surgery in multinodular goiter? PLoS One 2016;11:e0168654.
  • 34 Kaliszewski K, Diakowska D, Ziętek M, Knychalski B, Aporowicz M, Sutkowski K, et al. Thyroid incidentaloma as a “ PAIN “ phenomenon- does it always require surgery? Medicine (Baltimore) 2018;97:e13339.
  • 35 Chiricozzi A, Giovanardi G, Caro DR, Iannone M, De Simone C, Cannizzaro MV, et al. Characterization of comorbid conditions burdening hidradenitis suppurativa: A multicentric observational study. G Ital Dermatol Venereol 2020;155:335-40.
  • 36 Lapins J, Ye W, Nyrén O, Emtestam L. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol 2001;137:730-4.